Vaxcyte GAAP EPS of -$1.04 beats by $0.27
Source: SeekingAlpha
2025-05-08 04:15:01 ET
More on Vaxcyte
- Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer
- Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
- Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript
- Vinay Prasad to head FDA division regulating vaccines
- Top 10 Russell 2000 weekly gainers and losers as Wall Street crashes
Read the full article on Seeking Alpha
For further details see:
Vaxcyte GAAP EPS of -$1.04 beats by $0.27
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-5.35% G/L:
$53.39 Last:
575,994 Volume:
$57.06 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
